70% of medicines given to children have never been studied in pediatric populations. Children who need treatments represent a relatively small population. This alone presents unique challenges for pediatric drug development. Since the 1990s, authorities around the world have worked to solve these issues, enacting legislations to encourage pediatric drug development plans—but there is still more to do. This two-part paper discusses the role global collaboration will play in bringing life-changing drugs to children who need them most. Download to read Part Two or click here to read Part One.
Explore related content and topics
Newsletter
Industry Watch
In this second week of March, we’re bringing our readers news of what we can expect next from CRISPR gene-editing therapies after scientists in the…
Page
Mark Sorrentino, MD, MS, VP, Center for Vaccine Research and Center for Pediatric Clinical Development
We measure our HQ with actions, experiences, and intentions. Nowhere is that more evident that in the stories of our subject matter experts. We want…
Blog
Ask the Experts: Understanding Juvenile Idiopathic Arthritis
In light of JIA Awareness Month, its treatments, its stigma, and more, we spoke with Dr. Johnny Peppers, Executive Director of Drug Development for…